Morgan Ebert, Managing Editor

Hormone therapy was linked as a potential preventative treatment for adhesive capsulitis in menopausal women, according to a study presented at the North American Menopause Society Annual Meeting.

In a presentation at the North American Menopause Society Annual Meeting, investigators found these signs of menopause are 2 very separate symptoms and have different effects on stress and depression in menopausal women.

In a poster presentation at the North American Menopause Society Annual Meeting, researchers found that diets high in oil, meat, salt, sugar, and coffee contributed to menstrual cramps.

Knowing what is normal and abnormal with the vulvovaginal area is crucial for accurate diagnosis, according to a presentation at the 25th Annual Premier Women's Healthcare Conference held in Houston, Texas.

Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.

Marina Sirota, PhD, associate professor of pediatrics at the University of California, San Francisco, spoke about the new March of Dimes Prematurity Research Center at UCSF and the impact they hope their research will have on the future of preterm birth.

Marina Sirota, PhD, associate professor of pediatrics at the University of California, San Francisco, spoke about the new March of Dimes Prematurity Research Center at UCSF and the impact they hope their research will have on the future of preterm birth.

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen

The FDA has approved cetrorelix acetate for injection, a generic version of Cetrotide, for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.

Myovant Sciences and Pfizer announces the US Food and Drug Administration has approved Myfembree (relugolix combination tablets) for the once-daily treatment of moderate-to-severe endometriosis-associated pain.

If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).

Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).

John Martin, MD, chief medical officer at Butterfly Network, discusses a recent study published in NEJM Evidence, which investigated Butterfly iQ vs a commercial ultrasound machine to detect gestational age.

Contemporary OBGYN® sat down with John Martin, MD, chief medical officer of Butterfly Network Inc., to discuss the Butterfly iQ+, the world's only single-probe, whole-body ultrasound solution.

Perrigo’s HRA Pharma has submitted an application to the US Food and Drug Administration (FDA) for possible future approval of the first-ever OTC birth control pill.

US President Joe Biden signed an executive order Friday protecting nationwide access to abortion and contraception.

Bethany Corbin, Esq., sits down with Contemporary OB/GYN® to discuss the recent Supreme Court ruling overturning Roe v Wade and striking down almost 50 years of abortion precedent.

The United States Supreme Court voted to overturn Roe v Wade on Friday, eliminating the constitutional right to an abortion, and leaving the question of abortion rights to the states.

Data is scare for a comparison of the efficacy of onabotulinumtoxinA for treatment of overactive bladder between patients treated with 1 oral overactive bladder medication vs patients treated with more than 1.

The authors propose that moderate and high physical activity levels tend to be linked with a lower risk of constipation in adults following a meta-analysis of over 3,000 studies.

Health literacy is an integral part of a patient’s ability to make informed health decisions, especially when it comes to chronic pelvic pain (CPP).

The use of dynamic MRI for pelvic organ prolapse is essential for properly counseling patients and interpreting radiographic findings.

Currently approved for the treatment of vulvovaginal candidiasis (VVC), and if the sNDA is approved, ibrexafungerp (Brexafemme; Scynexis) would be the first and only oral non-azole medication for the prevention of recurrent VVC.

Uterine cancer is currently the only cancer type not covered by the World Trade Center (WTC) Health Program.

The US Food and Drug Administration has accepted to review the supplemental New Drug Application for Myfembree for the potential treatment of heavy menstrual bleeding associated with uterine fibroids for up to 2 years.

From COVID-19 to climate change to vulvovaginal candidiasis, the annual meeting offered something for everyone.

Bassem Maximos, MD, MPH, FACOG, discusses 2 recent studies investigating nonhormomal contraceptive gel Phexxi (Evofem Biosciences) for the potential treatment of UTIs and improvement in sexual satisfaction.

Tracy MacNeal, president and CEO of Materna Medical, sits down to discuss the company's recently FDA-cleared Milli Vaginal Dilator for vaginismus and associated dyspareunia, as well as a potential new use for the device currently being studied.

Erin Carey, MD, tackles the different methods for pain management in endometriosis during her presentation at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting.